BioCryst Pharmaceuticals Inc (NAS:BCRX)
$ 7.78 0.11 (1.43%) Market Cap: 1.61 Bil Enterprise Value: 2.09 Bil PE Ratio: 0 PB Ratio: 0 GF Score: 78/100

BioCryst Pharmaceuticals Inc at H C Wainwright Global Investment Conference (Virtual) - On-Demand Transcript

Sep 13, 2021 / 11:00AM GMT
Release Date Price: $15.49 (+1.91%)
Andrew S. Fein
H.C. Wainwright & Co, LLC, Research Division - MD of Equity Research & Senior Healthcare Analyst

Hello, everyone. I'm Andrew Fein. I'm 1 of the biotechnology analysts at H.C. Wainwright. It's my pleasure for the next company -- excuse me, to introduce the next company speaking today will be BioCryst Pharmaceuticals. I've the whole gang here for us. So hopefully, we can cover a lot of topics. Maybe the best place to start just handing it off to the company's CEO, Jon Stonehouse, to kind of lay the landscape in terms of where things are and what we can kind of expect in the next few quarters from the company.

Jon P. Stonehouse
BioCryst Pharmaceuticals, Inc. - CEO, President & Executive Director

Sure. And, Andy, thanks for inviting us to your health care conference. I wish we were doing this face-to-face, but I guess we won't do it for now. So let me quickly say that with me today is Charlie Gayer, our Chief Commercial Officer; Anthony Doyle, our Chief Financial Officer; Bill Sheridan, our Chief Medical Officer; and John Bluth, our

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot